---
document_datetime: 2023-09-21 17:56:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/palonosetron-accord-epar-all-authorised-presentations_en.pdf
document_name: palonosetron-accord-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6997347
conversion_datetime: 2025-12-18 22:09:53.119018
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name     | Strength        | Pharmaceutical form    | Route of administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|---------------------|-----------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/16/1104/001 | Palonosetron Accord | 250 microgra ms | Solution for injection | Intravenous use           | vial (glass)          | 5 ml                      | 1 vial      |

## NOTE:

## This is a sample English Annex A template only.

The English Annex A template is not provided as it is prepared by the European Medicines Agency. Translations of Annex A must be in line and consistent with the adopted English product information annexes of the product concerned.